Please login to the form below

Not currently logged in
Email:
Password:

Oral agent meets MS trial primary endpoint

Sanofi-aventis' teriflunomide has reached the primary endpoint of reducing the annualised relapse rate of relapsing MS in a phase III study

Teriflunomide, a novel oral disease modifier under investigation by sanofi-aventis (S-A) for the treatment of relapsing multiple sclerosis (RMS), has been shown in the phase III TEMSO trial to reduce annualised relapse rate by 31 per cent, compared with placebo. This means the trial attained its primary endpoint of statistically significantly reducing annualised relapse rate. 

In the two-year trial, which included 1,088 RMS patients, teriflunomide was also shown to be well tolerated, to reduce disease activity (as measured by various magnetic resonance imaging [MRI] metrics) and to reduce the risk of disease progression by 30 per cent at the higher dose (14mg) and by 24 per cent for the lower (7mg) dose.

The trial results were announced on October 15 at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) congress in Gothenburg, Sweden. Along with the TEMSO results, eight-year follow-up results of an open-label extension to a phase II study, demonstrating long-term safety, were presented. 

TOWER and TENERE, two other phase III trials of teriflunomide in RMS patients, are ongoing. TOPIC, a phase III trial of teriflunomide in early MS or clinically isolated syndrome (CIS) patients, is also in progress.

"We were very satisfied to see how TEMSO demonstrated that teriflunomide successfully reduced relapse rate but also reduced the time to disability progression for the highest dose with a favourable safety profile for multiple sclerosis patients with relapses and emerges as a potential new first-line treatment option in this patient population," said Dr Paul O'Connor, director of the MS Clinic at St Michael's Hospital, Toronto, Canada and principal investigator of the TEMSO study.

These positive results represent the latest in a series of announcements about oral MS therapies. Merck Serono's cladribine recently received a negative opinion from the European Medical Association's (EMA) Committee for Medicinal Products for Human Use (CHMP), while Novartis' Gilenya (fingolimod) has gained approval from the US Food and Drug Administration (FDA).

18th October 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

Theresa Heggie
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
Theresa Heggie talks about the biotech’s 16-year path to market, and the promise of its ‘gene silencing’ medicines...
patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...

Infographics